Palbociclib-propargyl is primarily utilized in the field of medicinal chemistry and cancer research. It serves as a key intermediate in the synthesis of more complex molecules, particularly those targeting cyclin-dependent kinases (CDKs). These kinases play a crucial role in regulating cell cycle progression, making them important targets for cancer therapy. The propargyl group in Palbociclib-propargyl allows for further chemical modifications through click chemistry, enabling the development of novel drug candidates with enhanced efficacy and selectivity. This compound is instrumental in the design and optimization of CDK inhibitors, which are used to treat various types of cancers, including breast cancer, by inhibiting the proliferation of cancer cells.